Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis

Table 1

Baseline characteristics of the study population.

Characteristics	Baseline data
Subjects	10
Male	10
Female	0
Age (years)	63 (44–73)
Smokers	0
Ex-smokers	10
Nonsmokers	0
Prior treatment (steroids) received	3
Other treatment received	3
VATS	6
FVC %pred	59.2 ± 17.1
TLC %pred	53.9 ±10.2
DLCO  %pred	39.4 ± 9.3
6MWD (meters)	441 ±124.5
PA-aO2 (mmHg)	27.4 ±11.5
sPAP (by echocardiography) mmHg	37.2 ± 19.6

Data are presented as median (range), no (total) or mean ± SD, unless stated otherwise.
6MWD: 6-minute walking distance, FVC: forced vital capacity, NA: nonapplicable, P_A-aO₂: alveolar-arterial gradient of oxygen tension, sPAP: systolic pulmonary artery pressure, TLC: total lung capacity.